Compare ECL & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ECL | ALNY |
|---|---|---|
| Founded | 1923 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.6B | 60.1B |
| IPO Year | N/A | 2004 |
| Metric | ECL | ALNY |
|---|---|---|
| Price | $257.43 | $404.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 27 |
| Target Price | $294.27 | ★ $483.89 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 10-28-2025 | 10-30-2025 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.95 | 0.33 |
| Revenue | ★ $15,890,400,000.00 | $3,210,070,000.00 |
| Revenue This Year | $3.03 | $69.60 |
| Revenue Next Year | $5.35 | $42.67 |
| P/E Ratio | ★ $37.05 | $1,226.18 |
| Revenue Growth | 1.38 | ★ 53.24 |
| 52 Week Low | $221.62 | $205.87 |
| 52 Week High | $286.04 | $495.55 |
| Indicator | ECL | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 41.44 | 32.73 |
| Support Level | $251.75 | $420.30 |
| Resistance Level | $276.62 | $479.79 |
| Average True Range (ATR) | 4.78 | 17.95 |
| MACD | -1.24 | -4.21 |
| Stochastic Oscillator | 22.78 | 0.83 |
Ecolab produces and markets cleaning and sanitation products for the industrial manufacturing, hospitality, healthcare, and life sciences markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. Additionally, Ecolab sells customized water management solutions across its end markets. The company has a strong hold on the US market and is growing its presence abroad.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.